KOSAN BIOSCIENCES
Kosan Biosciences Incorporated, a cancer therapeutics company, focuses on developing various classes of anticancer agents through clinical development. Its product KOS-953, a Hsp90 inhibitor is in Phase III clinical trial in combination with Velcade for multiple myeloma, as well as in Phase II clinical trial in combination with Herceptin for HER2-positive metastatic breast cancer. The company's product portfolio also includes KOS-1584, an epothilone anticancer product candidate evaluated in dose... -escalating Phase I clinical trial in patients with solid tumors; KOS-1803, a preclinical stage product for cancer; KOS-2187, a potent motilin receptor agonist that is in Phase I clinical testing for the treatment of GERD. In addition, Kosan Biosciences develops KOS-2464, a preclinical stage product for cancer. The company was founded in 1995 and is based in Hayward, California. As of June 25, 2008, Kosan Biosciences Incorporated operates as a subsidiary of Bristol-Myers Squibb Co.
KOSAN BIOSCIENCES
Industry:
Biotechnology Therapeutics
Founded:
1995-01-01
Address:
Hayward, California, United States
Country:
United States
Total Employee:
51+
Status:
Active
Total Funding:
3 M USD
Similar Organizations
Remedy Plan Therapeutics
Remedy Plan is a pre-clinical cancer therapeutics company developing first-in-class small molecule drugs that differentiate cancer cells.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Kingsbridge Capital
Kingsbridge Capital investment in Venture Round - Kosan Biosciences